Selected research
Industry Research
Flu Prevention Industry Research Report 2026
Market perspective
The global Flu Prevention market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Flu Prevention is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Flu Prevention is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Flu Prevention is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Flu Prevention include AstraZeneca, BCHT, CSL, KM Biologics, Sinovac, GSK, Hualan Bio, Viatris and Jiangsu GDK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Flu Prevention market in terms of revenue (US$ million) and, where applicable, sales volume (M Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Flu Prevention Market by Company
AstraZeneca
BCHT
CSL
KM Biologics
Sinovac
GSK
Hualan Bio
Viatris
Jiangsu GDK
Sanofi
Changchun Institute of Biological
Flu Prevention Segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Flu Prevention Segment by Application
6 Months to 3 Years
> 3 Years
Flu Prevention Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Flu Prevention market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Flu Prevention and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Flu Prevention.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Flu Prevention manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Flu Prevention by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Flu Prevention in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Trivalent Influenza Vaccine
- Quadrivalent Influenza Vaccine
Applications
- 6 Months to 3 Years
- > 3 Years
Companies covered
- AstraZeneca
- BCHT
- CSL
- KM Biologics
- Sinovac
- GSK
- Hualan Bio
- Viatris
- Jiangsu GDK
- Sanofi
- Changchun Institute of Biological
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Flu Prevention Market Size (2021-2032)
- 2.2.2 Global Flu Prevention Sales (2021-2032)
- 2.2.3 Global Flu Prevention Market Average Price (2021-2032)
- 2.3 Flu Prevention by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Trivalent Influenza Vaccine
- 2.3.3 Quadrivalent Influenza Vaccine
- 2.4 Flu Prevention by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 6 Months to 3 Years
- 2.4.3 > 3 Years
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Flu Prevention Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Flu Prevention Sales (M Doses) of Manufacturers (2021-2026)
- 3.3 Global Flu Prevention Revenue of Manufacturers (2021-2026)
- 3.4 Global Flu Prevention Average Price by Manufacturers (2021-2026)
- 3.5 Global Flu Prevention Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Flu Prevention, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Flu Prevention, Product Type & Application
- 3.8 Global Manufacturers of Flu Prevention, Established Date
- 3.9 Global Flu Prevention Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AstraZeneca
- 4.1.1 AstraZeneca Company Information
- 4.1.2 AstraZeneca Business Overview
- 4.1.3 AstraZeneca Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AstraZeneca Flu Prevention Product Portfolio
- 4.1.5 AstraZeneca Recent Developments
- 4.2 BCHT
- 4.2.1 BCHT Company Information
- 4.2.2 BCHT Business Overview
- 4.2.3 BCHT Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 BCHT Flu Prevention Product Portfolio
- 4.2.5 BCHT Recent Developments
- 4.3 CSL
- 4.3.1 CSL Company Information
- 4.3.2 CSL Business Overview
- 4.3.3 CSL Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CSL Flu Prevention Product Portfolio
- 4.3.5 CSL Recent Developments
- 4.4 KM Biologics
- 4.4.1 KM Biologics Company Information
- 4.4.2 KM Biologics Business Overview
- 4.4.3 KM Biologics Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 KM Biologics Flu Prevention Product Portfolio
- 4.4.5 KM Biologics Recent Developments
- 4.5 Sinovac
- 4.5.1 Sinovac Company Information
- 4.5.2 Sinovac Business Overview
- 4.5.3 Sinovac Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sinovac Flu Prevention Product Portfolio
- 4.5.5 Sinovac Recent Developments
- 4.6 GSK
- 4.6.1 GSK Company Information
- 4.6.2 GSK Business Overview
- 4.6.3 GSK Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GSK Flu Prevention Product Portfolio
- 4.6.5 GSK Recent Developments
- 4.7 Hualan Bio
- 4.7.1 Hualan Bio Company Information
- 4.7.2 Hualan Bio Business Overview
- 4.7.3 Hualan Bio Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hualan Bio Flu Prevention Product Portfolio
- 4.7.5 Hualan Bio Recent Developments
- 4.8 Viatris
- 4.8.1 Viatris Company Information
- 4.8.2 Viatris Business Overview
- 4.8.3 Viatris Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Viatris Flu Prevention Product Portfolio
- 4.8.5 Viatris Recent Developments
- 4.9 Jiangsu GDK
- 4.9.1 Jiangsu GDK Company Information
- 4.9.2 Jiangsu GDK Business Overview
- 4.9.3 Jiangsu GDK Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Jiangsu GDK Flu Prevention Product Portfolio
- 4.9.5 Jiangsu GDK Recent Developments
- 4.10 Sanofi
- 4.10.1 Sanofi Company Information
- 4.10.2 Sanofi Business Overview
- 4.10.3 Sanofi Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sanofi Flu Prevention Product Portfolio
- 4.10.5 Sanofi Recent Developments
- 4.11 Changchun Institute of Biological
- 4.11.1 Changchun Institute of Biological Company Information
- 4.11.2 Changchun Institute of Biological Business Overview
- 4.11.3 Changchun Institute of Biological Flu Prevention Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Changchun Institute of Biological Flu Prevention Product Portfolio
- 4.11.5 Changchun Institute of Biological Recent Developments
5 Global Flu Prevention Market Scenario by Region
- 5.1 Global Flu Prevention Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Flu Prevention Sales by Region: 2021-2032
- 5.2.1 Global Flu Prevention Sales by Region: 2021-2026
- 5.2.2 Global Flu Prevention Sales by Region: 2027-2032
- 5.3 Global Flu Prevention Revenue by Region: 2021-2032
- 5.3.1 Global Flu Prevention Revenue by Region: 2021-2026
- 5.3.2 Global Flu Prevention Revenue by Region: 2027-2032
- 5.4 North America Flu Prevention Market Facts & Figures by Country
- 5.4.1 North America Flu Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Flu Prevention Sales by Country (2021-2032)
- 5.4.3 North America Flu Prevention Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Flu Prevention Market Facts & Figures by Country
- 5.5.1 Europe Flu Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Flu Prevention Sales by Country (2021-2032)
- 5.5.3 Europe Flu Prevention Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Flu Prevention Market Facts & Figures by Country
- 5.6.1 Asia Pacific Flu Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Flu Prevention Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Flu Prevention Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Flu Prevention Market Facts & Figures by Country
- 5.7.1 South America Flu Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Flu Prevention Sales by Country (2021-2032)
- 5.7.3 South America Flu Prevention Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Flu Prevention Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Flu Prevention Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Flu Prevention Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Flu Prevention Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Flu Prevention Sales by Type (2021-2032)
- 6.1.1 Global Flu Prevention Sales by Type (2021-2032) & (M Doses)
- 6.1.2 Global Flu Prevention Sales Market Share by Type (2021-2032)
- 6.2 Global Flu Prevention Revenue by Type (2021-2032)
- 6.2.1 Global Flu Prevention Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Flu Prevention Revenue Market Share by Type (2021-2032)
- 6.3 Global Flu Prevention Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Flu Prevention Sales by Application (2021-2032)
- 7.1.1 Global Flu Prevention Sales by Application (2021-2032) & (M Doses)
- 7.1.2 Global Flu Prevention Sales Market Share by Application (2021-2032)
- 7.2 Global Flu Prevention Revenue by Application (2021-2032)
- 7.2.1 Global Flu Prevention Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Flu Prevention Revenue Market Share by Application (2021-2032)
- 7.3 Global Flu Prevention Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Flu Prevention Value Chain Analysis
- 8.1.1 Flu Prevention Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Flu Prevention Production Mode & Process
- 8.2 Flu Prevention Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Flu Prevention Distributors
- 8.2.3 Flu Prevention Customers
9 Global Flu Prevention Analyzing Market Dynamics
- 9.1 Flu Prevention Industry Trends
- 9.2 Flu Prevention Industry Drivers
- 9.3 Flu Prevention Industry Opportunities and Challenges
- 9.4 Flu Prevention Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst